Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2019

At a glance

  • Drugs Sarilumab (Primary) ; Prednisone
  • Indications Polymyalgia rheumatica
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 24 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 01 Aug 2018 New source identified and integrated (ClinicalTrials.gov: NCT03600818).
    • 17 Jul 2018 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top